PanCareSurPass Project HL7 FHIR Implementation Guide
0.2.0 - CI Build
150
PanCareSurPass Project HL7 FHIR Implementation Guide
0.2.0 - CI Build
150
PanCareSurPass Project HL7 FHIR Implementation Guide, published by PanCareSurPass Project. This guide is not an authorized publication; it is the continuous build for version 0.2.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/pcsp/ and changes regularly. See the Directory of published versions
Document Details
Profile: Bundle: Survivor Passport
Preliminary Document at 2025-06-11 07:41:51+0000 by Identifier: test for NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, ))
Document Subject
Language: es-ES
Profile: Patient: PCSP
NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, ))
| Contact Detail | belensmicorr@gggmail.com | ||
| Language: | Spanish (Spain) | ||
| Patient Mother's Maiden Name | APELLIDO2 | ||
| Patient Birth Place | CALLEFALSA123 Valencia Valencia España | ||
Document Content
Primary Cancer Diagnosis and Treatment Summary
Chemotherapy Treatments
Care Plan
Entry 2 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Patient/PatientHulafe-1
Resource Patient:
Language: es-ES
Profile: Patient: PCSP
NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, ))
Contact Detail belensmicorr@gggmail.com Language: Spanish (Spain) Patient Mother's Maiden Name APELLIDO2 Patient Birth Place CALLEFALSA123 Valencia Valencia España
Entry 3 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Condition/PrimaryCancerHulafe-1
Resource Condition:
Language: es-ES
Profile: Condition: Primary Cancer
Condition Asserted Date: 2021
Histology-Morphology-Behavior Extension: 8260/3 - Carcinoma papilar de tiroides
code: Carcinoma tiroides
bodySite: C73.9
encounter: Encounter: status = finished; class = ambulatory (ActCode#AMB)
Stages
Summary pT1a note:
Alergia al epitelio de gato
Entry 4 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Encounter/EncHulafe-1
Resource Encounter:
Language: es-ES
status: completed
class: ambulatory
serviceProvider: Organization Hospital Universitari i Politècnic La Fe
Entry 5 - fullUrl = http://hl7.eu/fhir/ig/pcsp/MedicationAdministration/ChemoHulafe-1-Ciclofosfamide
Resource MedicationAdministration:
Act Location: Location Hospital la Fe
Resource related information: Observation Cumulative dose received by a patient for a specific drug.
status: completed
Entry 6 - fullUrl = http://hl7.eu/fhir/ig/pcsp/MedicationAdministration/ChemoHulafe-1-Metotrexato
Resource MedicationAdministration:
Act Location: Location Hospital la Fe
Resource related information: Observation Cumulative dose received by a patient for a specific drug.
status: completed
Entry 7 - fullUrl = http://hl7.eu/fhir/ig/pcsp/MedicationAdministration/ChemoHulafe-1-Vincristina
Resource MedicationAdministration:
Act Location: Location Hospital la Fe
Resource related information: Observation Cumulative dose received by a patient for a specific drug.
status: completed
Entry 8 - fullUrl = http://hl7.eu/fhir/ig/pcsp/MedicationAdministration/ChemoHulafe-1-Citarabina
Resource MedicationAdministration:
Act Location: Location Hospital la Fe
Resource related information: Observation Cumulative dose received by a patient for a specific drug.
status: completed
Entry 9 - fullUrl = http://hl7.eu/fhir/ig/pcsp/MedicationStatement/ChemoHulafe-1-corticosteroids
Resource MedicationStatement:
Profile: MedicationStatement: Chemotherapy
status: not-taken
status: recorded
Dosages
Timing Once
Entry 10 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Observation/ChemoHulafe-1-Ciclofosfamide-dose
Resource Observation:
status: Final
code: Cumulative dose received by a patient for a specific drug.
value: 3000 mg/m2 (Details: UCUM codemg/m2 = 'mg/m2')
method: Calculation technique
Entry 11 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Observation/ChemoHulafe-1-Metotrexato-dose
Resource Observation:
status: Final
code: Cumulative dose received by a patient for a specific drug.
value: 12000 mg/m2 (Details: UCUM codemg/m2 = 'mg/m2')
method: Calculation technique
Entry 12 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Observation/ChemoHulafe-1-Vincristina-dose
Resource Observation:
status: Final
code: Cumulative dose received by a patient for a specific drug.
value: 5.4 mg/m2 (Details: UCUM codemg/m2 = 'mg/m2')
method: Calculation technique
Entry 13 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Observation/ChemoHulafe-1-Citarabina-dose
Resource Observation:
status: Final
code: Cumulative dose received by a patient for a specific drug.
value: 920 mg/m2 (Details: UCUM codemg/m2 = 'mg/m2')
method: Calculation technique
Entry 14 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Organization/OrgHulafe-1
Resource Organization:
Language: es-ES
Profile: Organization: Primary Treatment Center / Center of diagnosis
active: true
name: Hospital Universitari i Politècnic La Fe
alias: La Fe
contact
telecom: +34 961 244 000, prensa_lafe@gva.es
address: Avinguda de Fernando Abril Martorell, nº 106 Valencia Comunidad Valenciana 46026 ES (work)
Entry 15 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Location/ChemoHulafe-1-Location
Resource Location:
Profile: Location: PCSP
name: Hospital la Fe
address: Valencia Spain
Entry 16 - fullUrl = http://hl7.eu/fhir/ig/pcsp/CarePlan/CarePlanExample-1
Resource CarePlan:
FOLLOW-UP RECOMMENDATIONS
Here below are listed personalized follow-up recommendations, based on the treatments you received. These advices are based on international experience with people who received similar treatments as you.
They are meant to prevent and/or diagnose at an early stage possible future complications.
It is possible that over time these recommendations will be updated according to new clinical situations and/or new data in the scientific literature. We will make all possible efforts in order to update about any new update.
We encourage you to report to your doctor any persistent symptom you might have, in order to allow an early identification of its cause.
General recommendations
A healthy lifestyle helps to maintain physical and mental wellbeing, as well as preventing possible diseases such as cardiovascular complications, tumors, and psychological problems.
We therefore recommend you to:
- Maintain a normal body weight and engage in regular physical activity.
- Eat plenty of fruits and vegetables, and reduce fat, sugar, and salt intake.
- Don't smoke and avoid excessive alcohol intake.
- Maintain proper dental hygiene.
- Avoid excessive sun exposure and remember to use high-protection sunscreen.
- Check your blood pressure periodically.
- Report to your health care provider any experience of chronic pain, excessive fatigue and/or deterioration of performance in your daily activities (study, work and/or exercise).
- Adhere to all cancer screening programs that will be offered by the health system.
You might be at risk of Because you were treated with We therefore recommend you to Subsequent thyroid cancer
- RT to a vol exposing the thyroid gland
Counselling regarding the increased risk for developing differentiated thyroid to inform their HCP if they detect a thyroid mass (independent of the presence or absence of associated symptoms), every 5 years - Physical examination of the neck as part of a complete physical examination, whenever a survivor is assessed by a HCP - Counselling regarding options for differentiated thyroid carcinoma surveillance, at least every 5 years If the decision to commence surveillance is made, make a shared decision for one of these two surveillance modalities: - Neck palpation, every 1-2 years, starting 5 years after radiotherapy, or - Thyroid ultrasonographyw, every 3-5 years, starting 5 years after radiotherapy Subsequent breast cancer
- RT >= 10 Gy to a vol exposing the breasts
Mammography and breast MRI every year if > 25 years of age or > 8 years from radiation, whichever occurs last Cardiac problems (High risk)
- RT >= 35 Gy to a vol exposing the heart
- Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2
A physical cardiac examination at every LTFU visit, at least every 5 years. Screening for modifiable cardiovascular risk factors (hypertension, diabetes, dyslipidaemia, obesity, smoking and low levels of physical activity). - ECG once at entry into LTFU. Repeat ECG once after the age of 18 years if entry into LTFU was at a younger age. - Echocardiogram with specific attention to left ventricular systolic function, to valvular structure and function and to the pericardium, starting 2 years after treatment and at least every 2-3 years; Echocardiogram with specific attention to left ventricular function, prior to pregnancy or in the first trimester, if female - Refer to a cardiologist if an abnormal ejection fraction or if other abnormalities are identified - Refer for interventions to help avert the risk of symptomatic cardiomyopathy if modifiable cardiovascular risk factors are identified Refer to a cardiologist if an abnormal ejection fraction or if other abnormalities are identified - Refer for interventions to help avert the risk of symptomatic cardiomyopathy if modifiable cardiovascular risk factors are identified
Entry 17 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Observation/ObservationRiskFactor-1
Resource Observation:
Profile: Observation: Risk Factor
status: Final
code: Risk factor
subject: APELLIDO1
effective: 2022-05-12 --> (ongoing)
value: RT to a vol exposing the thyroid gland
Entry 18 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Observation/ObservationRiskFactor-2
Resource Observation:
Profile: Observation: Risk Factor
status: Final
code: Risk factor
subject: APELLIDO1
effective: 2022-05-12 --> (ongoing)
value: RT >= 10 Gy to a vol exposing the breasts
Entry 19 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Observation/ObservationRiskFactor-3
Resource Observation:
Profile: Observation: Risk Factor
status: Final
code: Risk factor
subject: APELLIDO1
effective: 2022-05-12 --> (ongoing)
value: RT >= 35 Gy to a vol exposing the heart
Entry 20 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Observation/ObservationRiskFactor-4
Resource Observation:
Profile: Observation: Risk Factor
status: Final
code: Risk factor
subject: APELLIDO1
effective: 2022-05-12 --> (ongoing)
value: Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2
Entry 21 - fullUrl = http://hl7.eu/fhir/ig/pcsp/DocumentReference/DocumentReferenceExample-1
Resource DocumentReference:
Profile: DocumentReference: PCSP
status: Current
docStatus: Preliminary
type: Childhood Cancer Survivor Passport
subject: APELLIDO1
date: 2022-06-14 13:28:17+0200
content
Attachments
ContentType Language Data Title Creation application/pdf es-ES (base64 data - 251,792 base64 chars) Survivor Passport of APELLIDO1 2022-06-14
IG © 2021+ PanCareSurPass Project. Package hl7.eu.fhir.pcsp#0.2.0 based on FHIR 4.0.1. Generated 2025-09-03
Links: Table of Contents |
QA Report
The PanCareSurPass Research and Innovation Action has received funding from the European Union's Horizon 2020
research and innovation programme under grant agreement No. 899999.
